Testing effectiveness (Phase 2)Active Not RecruitingNCT05458297
What this trial is testing
Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Merck Sharp & Dohme LLC 223